CLVR RSI Chart
Last 7 days
35.9%
Last 30 days
-53.0%
Last 90 days
-29.8%
Trailing 12 Months
755.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 15.3M | 16.2M | 17.2M | 17.4M |
2022 | 16.9M | 17.4M | 16.2M | 16.4M |
2021 | 26.5M | 28.2M | 28.3M | 15.4M |
2020 | 12.3M | 16.9M | 21.4M | 25.9M |
2019 | 0 | 0 | 0 | 7.8M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 08, 2024 | hague henry r iii | sold | -562 | 3.3108 | -170 | chief financial officer |
Feb 27, 2024 | hague henry r iii | sold | -1,623 | 3.95 | -411 | chief financial officer |
Jan 19, 2024 | fajardo andres | sold | -4,501 | 2.884 | -1,561 | chief executive officer |
Jan 19, 2024 | wilches julian | sold | -377 | 2.884 | -131 | chief regulatory officer |
Dec 20, 2023 | fajardo andres | sold | -360 | 2.0367 | -177 | chief executive officer |
Dec 20, 2023 | wilches julian | sold | -274 | 2.0367 | -135 | chief regulatory officer |
Jul 18, 2023 | hague henry r iii | sold | -335 | 0.2152 | -1,560 | chief financial officer |
Jul 18, 2023 | wilches julian | sold | -174 | 0.2152 | -813 | chief regulatory officer |
Which funds bought or sold CLVR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | unchanged | - | 122 | 214 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 4.00 | 4.00 | -% |
May 15, 2024 | Nemes Rush Group LLC | unchanged | - | 88.00 | 156 | -% |
May 15, 2024 | Walleye Capital LLC | unchanged | - | 10,158 | 18,220 | -% |
May 15, 2024 | Davidson Kempner Capital Management LP | unchanged | - | 7,344 | 11,313 | -% |
May 15, 2024 | Penserra Capital Management LLC | unchanged | - | 14,000 | 24,000 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -17.15 | 4,219 | 8,776 | -% |
May 15, 2024 | GTS SECURITIES LLC | new | - | 440 | 440 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -438 | - | -% |
May 15, 2024 | Royal Bank of Canada | added | 573 | 1,000 | 1,000 | -% |
Unveiling Clever Leaves Holdings Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Clever Leaves Holdings Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Clever Leaves Holdings Inc. News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Revenue | 21.4% | 4,638,000 | 3,820,000 | 4,981,000 | 3,978,000 | 4,402,000 | 2,867,000 | 4,100,000 | 5,041,000 | 4,194,000 | 4,031,000 | 3,672,000 | 3,477,000 | 17,121,000 | 3,917,000 | 1,939,000 | 2,914,000 | - |
Gross Profit | -117.8% | -346,000 | 1,942,000 | 2,726,000 | 2,234,000 | 844,000 | 1,299,000 | 2,481,000 | 2,593,000 | 970,000 | 1,931,000 | 1,768,000 | 2,140,000 | 2,272,000 | 2,073,000 | 907,000 | 2,161,000 | - |
Operating Expenses | -14.2% | 4,566,000 | 5,319,000 | 5,901,000 | 6,364,000 | 8,371,500 | 25,623,000 | 7,829,000 | 12,312,000 | 31,122,000 | 11,615,000 | 11,371,000 | 9,908,000 | 9,590,000 | 6,784,000 | 8,232,000 | 11,335,000 | - |
S&GA Expenses | -25.1% | 436,000 | 582,000 | 469,000 | 549,000 | -178,000 | 615,000 | 728,000 | 732,000 | 1,879,000 | 208,000 | 241,000 | 587,000 | 285,000 | 508,000 | 603,000 | 1,181,000 | - |
R&D Expenses | -20.2% | 233,000 | 292,000 | 403,000 | 212,000 | 605,000 | 343,000 | 359,000 | 412,000 | 509,000 | 454,000 | 305,000 | 278,000 | - | - | - | - | - |
EBITDA Margin | 58.1% | -1.06 | -2.54 | -3.68 | -3.56 | -3.88 | -3.47 | -1.75 | -2.42 | -2.65 | -0.70 | -0.95 | -1.01 | -0.90 | -1.98 | -2.51 | -3.42 | -5.40 |
Interest Expenses | - | - | - | - | - | 65,000 | - | - | 375,000 | 117,000 | - | - | 548,000 | -65,000 | - | - | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 30.6% | -5,046,000 | -7,271,000 | -3,261,000 | -4,151,000 | -7,348,000 | -24,841,000 | 1,856,000 | -13,761,000 | -22,994,000 | 1,009,000 | -8,942,000 | -13,754,000 | -846,000 | -6,106,000 | -8,748,000 | -10,175,000 | - |
EBT Margin | 58.3% | -1.13 | -2.71 | -3.86 | -3.75 | -4.07 | -3.69 | -1.95 | -2.64 | -2.91 | -0.80 | -1.05 | -1.11 | -1.00 | -2.15 | -2.72 | -3.72 | -5.86 |
Net Income | 1.0% | -5,085,000 | -5,138,000 | -3,595,000 | -4,081,000 | -28,816,000 | -20,163,000 | -1,046,000 | -16,140,000 | -24,000,000 | 995,000 | -8,956,000 | -13,765,000 | -2,686,000 | -5,094,000 | -8,753,000 | -10,186,000 | - |
Net Income Margin | 54.2% | -1.03 | -2.24 | -3.22 | -3.23 | -3.72 | -3.79 | -2.31 | -2.84 | -2.97 | -0.86 | -1.08 | -1.15 | -1.03 | -1.85 | -2.34 | -3.20 | -5.05 |
Free Cashflow | 39.9% | -1,387,000 | -2,309,000 | -1,731,000 | -6,112,000 | -4,547,000 | -5,640,000 | -8,599,000 | -11,586,000 | -9,370,000 | -10,328,000 | -10,972,000 | -12,843,000 | -4,061,000 | -3,586,000 | -9,103,000 | -8,876,000 | - |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | -17.3% | 31.00 | 38.00 | 43.00 | 46.00 | 52.00 | 81.00 | 105 | 127 | 116 | 141 | 150 | 159 | 166 | 96.00 |
Current Assets | -22.3% | 14.00 | 18.00 | 18.00 | 21.00 | 26.00 | 41.00 | 44.00 | 69.00 | 60.00 | 68.00 | 77.00 | 87.00 | 96.00 | 24.00 |
Cash Equivalents | 5.5% | 7.00 | 6.00 | 5.00 | 6.00 | 12.00 | 18.00 | 19.00 | 45.00 | 38.00 | 46.00 | 57.00 | 69.00 | 79.00 | 13.00 |
Inventory | -41.8% | 4.00 | 8.00 | 7.00 | 8.00 | 8.00 | 17.00 | 17.00 | 16.00 | 15.00 | 14.00 | 13.00 | 12.00 | 10.00 | 5.00 |
Net PPE | -3.4% | 12.00 | 13.00 | 13.00 | 13.00 | 14.00 | 29.00 | 30.00 | 30.00 | 31.00 | 30.00 | 29.00 | 27.00 | 26.00 | 24.00 |
Goodwill | - | - | - | - | - | - | - | - | - | - | 19.00 | 19.00 | 19.00 | 19.00 | 20.00 |
Liabilities | -13.1% | 7.00 | 8.00 | 9.00 | 9.00 | 12.00 | 12.00 | 21.00 | 45.00 | 43.00 | 53.00 | 71.00 | 74.00 | 71.00 | 46.00 |
Current Liabilities | -15.1% | 6.00 | 7.00 | 8.00 | 8.00 | 9.00 | 8.00 | 9.00 | 27.00 | 27.00 | 33.00 | 57.00 | 31.00 | 30.00 | 6.00 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | 6.00 | - | 27.00 | 7.00 | 27.00 |
Shareholder's Equity | -18.4% | 24.00 | 30.00 | 34.00 | 37.00 | 40.00 | 70.00 | 85.00 | 82.00 | 73.00 | 88.00 | 79.00 | 84.00 | 95.00 | 50.00 |
Retained Earnings | -2.6% | -198 | -193 | -188 | -184 | -180 | -152 | -131 | -130 | -114 | -90.74 | -91.73 | -82.78 | -69.01 | -31.93 |
Additional Paid-In Capital | -0.2% | 223 | 223 | 223 | 222 | 221 | 222 | 217 | 213 | 188 | 178 | 171 | 167 | 164 | 77.00 |
Accumulated Depreciation | 4.8% | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 8.00 | 7.00 | 6.00 | 6.00 | 5.00 | 4.00 | 4.00 | 3.00 | 1.00 |
Shares Outstanding | 0.1% | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 |
Float | - | - | - | 12.00 | - | - | - | 36.00 | - | - | - | 132 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Cashflow From Operations | 29.9% | -1,543 | -2,201 | -1,687 | -6,077 | -5,097 | -5,385 | -8,213 | -10,371 | -8,038 | -8,699 | -8,869 | -10,627 | -3,682 | -3,736 | -7,322 | -7,221 | - |
Share Based Compensation | -361.5% | -136 | 52.00 | 434 | 468 | -263 | 958 | 1,148 | 500 | 3,314 | 3,264 | 3,323 | 1,550 | 747 | 489 | -297 | 416 | - |
Cashflow From Investing | -24.3% | 2,056 | 2,717 | -44.00 | -35.00 | 550 | -255 | 2,112 | -1,215 | -1,332 | -1,629 | -2,103 | -2,216 | -379 | 150 | -1,781 | -1,655 | - |
Cashflow From Financing | -121.3% | -162 | 760 | 165 | -107 | -250 | 3,886 | -19,038 | 18,691 | 883 | -585 | -1,097 | 2,633 | 77,206 | 3,653 | -5,987 | 16,966 | - |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6,250 | - | - |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||
Revenue, net | $ 17,417,000 | $ 16,410,000 |
Cost of sales | (10,861,000) | (9,193,000) |
Gross profit | 6,556,000 | 7,217,000 |
Expenses | ||
General and administrative | 17,993,000 | 23,830,000 |
Sales and marketing | 2,036,000 | 1,897,000 |
Research and development | 1,140,000 | 1,719,000 |
Restructuring expenses | 0 | 6,449,000 |
Intangible asset impairment | 0 | 19,000,000 |
Depreciation and amortization | 981,000 | 1,241,000 |
Total expenses | 22,150,000 | 54,136,000 |
Loss from operations | (15,594,000) | (46,919,000) |
Other Expense (Income), net | ||
Interest expense and amortization of debt issuance cost | 46,000 | 2,672,000 |
Gain on remeasurement of warrant liability | (113,000) | (2,092,000) |
Loss (Gain) on investments | 3,738,000 | (6,851,000) |
Loss on debt extinguishment, net | 0 | 2,263,000 |
Foreign exchange loss | 433,000 | 963,000 |
Other expense, net | 31,000 | 220,000 |
Total other expense (income), net | 4,135,000 | (2,825,000) |
Loss before income taxes and equity investment loss | (19,729,000) | (44,094,000) |
Deferred income tax recovery | 0 | (6,650,000) |
Income tax provision | 68,000 | 296,000 |
Equity investment share of loss | 0 | 64,000 |
Loss from continuing operations | (19,797,000) | (37,804,000) |
Gain/(loss) from discontinued operations | 1,898,000 | (28,361,000) |
Net loss attributable to Clever Leaves Holdings Inc. common shareholders - basic | (17,899,000) | (66,165,000) |
Net loss attributable to Clever Leaves Holdings Inc. common shareholders - diluted | $ (17,899,000) | $ (66,165,000) |
Basic - continuing operations (in dollars per share) | $ (12.63) | $ (29.54) |
Diluted - continuing operations (in dollars per share) | (12.63) | (29.54) |
Basic - discontinued operations (in dollars per share) | 1.21 | (22.16) |
Diluted - discontinued operations (in dollars per share) | 1.21 | (22.16) |
Net loss per share - basic (in dollars per share) | (11.42) | (51.70) |
Net loss per share - diluted (in dollars per share) | $ (11.42) | $ (51.70) |
Weighted-average common shares outstanding - basic (in shares) | 1,567,601 | 1,279,746 |
Weighted-average common shares outstanding - diluted (in shares) | 1,567,601 | 1,279,746 |
Consolidated Statements of Financial Position - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current: | ||
Cash and cash equivalents | $ 6,831 | $ 12,449 |
Restricted cash | 70 | 439 |
Accounts receivable, net | 907 | 2,252 |
Prepaids, deposits and other receivables | 1,649 | 2,708 |
Inventories, net | 4,483 | 8,399 |
Total current assets | 13,940 | 26,247 |
Investment – Cansativa | 0 | 5,679 |
Property, plant and equipment, net of accumulated depreciation of $8,793 and $7,120 for the years ended December 31, 2023 and 2022, respectively | 12,321 | 13,963 |
Land held for sale | 1,500 | 1,500 |
Intangible assets, net | 2,653 | 3,354 |
Operating lease right-of-use assets, net | 829 | 1,303 |
Other non-current assets | 0 | 52 |
Total Assets | 31,243 | 52,098 |
Current: | ||
Accounts payable | 2,063 | 2,299 |
Accrued expense and other current liabilities | 2,844 | 4,238 |
Loans and borrowings, current portion | 498 | 465 |
Warrant liability | 0 | 113 |
Operating lease liabilities, current portion | 386 | 1,239 |
Deferred revenue | 20 | 1,072 |
Total current liabilities | 5,811 | 9,426 |
Loans and borrowings | 720 | 1,065 |
Operating lease liabilities — long-term | 483 | 1,087 |
Other long-term liabilities | 12 | 112 |
Total Liabilities | 7,026 | 11,690 |
Contingencies and commitments | ||
Shareholders’ equity | ||
Preferred shares, without par value, unlimited shares authorized, nil shares issued and outstanding for each of December 31, 2023 and 2022 | 0 | 0 |
Common shares, without par value, unlimited shares authorized: 1,727,698 and 1,454,559 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 0 | 0 |
Additional paid-in capital | 223,021 | 221,313 |
Accumulated deficit | (198,804) | (180,905) |
Total shareholders' equity | 24,217 | 40,408 |
Total liabilities and shareholders' equity | $ 31,243 | $ 52,098 |
Mr. Andres Fajardo | |
https://cleverleaves.com | |
Pharmaceuticals | |
400 |